BCL9 and ductal breast carcinoma in situ: Analysis of patient ductal in situ carcinoma (DCIS) revealed a significant correlation between high nuclear BCL9, another coactivator implicated in β-catenin triggering, and pathologic characteristics associated with DCIS recurrence as ER and PgR negative, high nuclear grade, and HER2 amplification/overexpression.